The nation of Zimbabwe has turned down a major US health deal valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential information.
This rejection became public after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesman later stated that the US was demanding access to health data for research and profit but refused to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued dialogue to secure a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Implications
Zimbabwe's decision follows a similar situation in Kenya, where a high court blocked a related deal with the US after legal challenges were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
As per reports, 16 nations in Africa have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no corresponding promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any certainty that the end products would be available to our population should a new pandemic emerge."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending structures already established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This system is intended to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued discussions with our US partners on how future co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but suggested that negotiations need to persist since much of the nation's HIV programmes relied on external financing.
"Where technical issues arise, including those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group added.
The situation emphasises the complex challenges between accepting much-needed international aid and protecting national sovereignty in an ever more data-driven world.